Rivaroxaban for a Patient with Class III Obesity: Case Report with Literature Review

Affiliations

¹ , BScPharm, ACPR, is a Clinical Pharmacist, Internal Medicine with the Peter Lougheed Center, Alberta Health Services, Calgary Zone, Calgary, Alberta.
² , MD, is a Clinical Lecturer with the Cumming School of Medicine, University of Calgary, Calgary, Alberta.
³ , MD, is an Internal Medicine Resident with the University of Calgary, Calgary, Alberta.
⁴ is a medical student with the University of Calgary, Calgary, Alberta.
⁵ , MD, MPH, is a Clinical Associate Professor with the Cumming School of Medicine, University of Calgary, Calgary, Alberta.

Duane Bates et al. Can J Hosp Pharm. 2018 Jan-Feb.

. 2018 Jan-Feb;71(1):36-43.

Epub 2018 Mar 7.

¹ , BScPharm, ACPR, is a Clinical Pharmacist, Internal Medicine with the Peter Lougheed Center, Alberta Health Services, Calgary Zone, Calgary, Alberta.
² , MD, is a Clinical Lecturer with the Cumming School of Medicine, University of Calgary, Calgary, Alberta.
³ , MD, is an Internal Medicine Resident with the University of Calgary, Calgary, Alberta.
⁴ is a medical student with the University of Calgary, Calgary, Alberta.
⁵ , MD, MPH, is a Clinical Associate Professor with the Cumming School of Medicine, University of Calgary, Calgary, Alberta.

No abstract available

Conflict of interest statement

Competing interests: None declared.

1. Twells LK, Gregory DM, Reddigan J, Midodzi WK. Current and predicted prevalence of obesity in Canada: a trend analysis. CMAJ Open. 2014;2(1):E18–26. doi: 10.9778/cmajo.20130016. - DOI - PMC - PubMed
1. Lentz SR. Thrombosis in the setting of obesity or inflammatory bowel disease. Blood. 2016;128(20):2388–94. doi: 10.1182/blood-2016-05-716720. - DOI - PubMed
1. Xarelto [product monograph] Mississauga (ON): Bayer Inc; 2015. Jul 20,
1. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sanset PM, Moll S. Use of direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–13. doi: 10.1111/jth.13323. - DOI - PMC - PubMed
1. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamics profile of rivaroxaban. Clin Pharmaokinet. 2014;53(1):1–16. doi: 10.1007/s40262-013-0100-7. - DOI - PMC - PubMed